Reviewing Neurogene (NASDAQ:NGNE) & Propanc Biopharma (NASDAQ:PPCB)

Propanc Biopharma (NASDAQ:PPCB) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Insider and Institutional Ownership

52.4% of Neurogene shares are owned by institutional investors. 28.7% of Propanc Biopharma shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Propanc Biopharma has a beta of 3.52, meaning that its share price is 252% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Profitability

This table compares Propanc Biopharma and Neurogene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Neurogene	N/A	-45.10%	-41.00%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Propanc Biopharma and Neurogene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1	0	0	0	1.00
Neurogene	1	0	4	1	2.83

Neurogene has a consensus target price of $83.67, indicating a potential upside of 130.87%. Given Neurogene’s stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Propanc Biopharma.

Earnings & Valuation

This table compares Propanc Biopharma and Neurogene”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92 million	($24.25)	-0.06
Neurogene	N/A	N/A	-$90.35 million	($5.03)	-7.20

Neurogene is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Neurogene beats Propanc Biopharma on 8 of the 12 factors compared between the two stocks.

About Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.